Arcellx (ACLX) Stock Forecast & Price Target

$85.24

+4.69 (+5.82%)

(As of 02:51 PM ET)

Arcellx - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 15 Analyst Ratings

Based on 15 Wall Street analysts who have issued ratings for Arcellx in the last 12 months, the stock has a consensus rating of "Buy." Out of the 15 analysts, 14 have given a buy rating, and 1 has given a strong buy rating for ACLX.

Consensus Price Target

$78.00
-8.49% Downside

High Forecast	$87.00
Average Forecast	$78.00
Low Forecast	$52.00

According to the 15 analysts' twelve-month price targets for Arcellx, the average price target is $78.00. The highest price target for ACLX is $87.00, while the lowest price target for ACLX is $52.00. The average price target represents a forecasted downside of -8.49% from the current price of $85.24.

Type	Current Forecast 9/20/23 to 9/19/24	1 Month Ago 8/21/23 to 8/20/24	3 Months Ago 6/22/23 to 6/21/24	1 Year Ago 9/20/22 to 9/20/23
Consensus Rating	Buy	Buy	Buy	Buy
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	13 Buy rating(s)	13 Buy rating(s)	10 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$78.00	$78.00	$78.00	$53.42
Forecasted Upside	-8.49% Downside	37.94% Upside	37.17% Upside	55.43% Upside

Why You Should NOT Trade This Market (Ad)

You'll be interested in our 5-Day Options Trading Challenge, starting September 23. So, what makes this different from every other options research you may have seen? Well, for starters... most of them want you to first BUY their service... which is usually thousands of dollars...

Just click here to get the full details on the 5-Day Options Trading Challenge, before this offer go

ACLX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ACLX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Arcellx Stock vs. The Competition

Type	Arcellx	Medical Companies	S&P 500
Consensus Rating Score	3.07	2.77	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	-7.13% Downside	968.13% Upside	6.74% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/9/2024	Cantor Fitzgerald 3 of 5 stars	R. Bienkowski Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
8/9/2024	Needham & Company LLC 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$81.00 ➝ $81.00	+54.05%
7/22/2024	Canaccord Genuity Group 1 of 5 stars		Reiterated Rating	Buy ➝ Buy	$85.00 ➝ $85.00	+35.87%
6/18/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$87.00 ➝ $87.00	+61.62%
5/31/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Amin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$70.00	+34.00%
5/15/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$82.00 ➝ $83.00	+63.97%
Trump Warns Gov. Can Confiscate Your Money. CBDC's give Gov. absolute (Ad) Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it. This means you must act NOW before it's too late.
5/14/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$85.00	+70.79%
5/13/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$82.00 ➝ $80.00	+64.20%
4/4/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$82.00	+29.75%
3/7/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$81.00	+11.03%
2/29/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$62.00 ➝ $73.00	+8.44%
2/29/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$63.00 ➝ $77.00	+14.38%
10/30/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform
10/17/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$52.00	+52.67%
10/12/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Graybosch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/10/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$39.00 ➝ $50.00	+10.52%
4/24/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$45.00 ➝ $58.00	+45.22%
3/30/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$35.00 ➝ $39.00	+27.74%
3/30/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$35.00 ➝ $39.00	+25.44%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:12 PM ET.

ACLX Forecast - Frequently Asked Questions

What is Arcellx's forecast for 2024?: According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Arcellx is $78.00, with a high forecast of $87.00 and a low forecast of $52.00.
Should I buy or sell Arcellx stock right now?: 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcellx in the last twelve months. There are currently 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACLX shares.
Does Arcellx's stock price have much upside?: According to analysts, Arcellx's stock has a predicted upside of 37.94% based on their 12-month stock forecasts.
What analysts cover Arcellx?: Arcellx has been rated by research analysts at Canaccord Genuity Group, Cantor Fitzgerald, and Needham & Company LLC in the past 90 days.
Do Wall Street analysts like Arcellx more than its competitors?: Analysts like Arcellx more than other "medical" companies. The consensus rating for Arcellx is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ACLX compares to other companies.